![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » PEGASYS + RIBAVIRIN AWARDED PRIORITY REVIEW STATUS BY JAPANESE REGULATORY AGENCY
PEGASYS + RIBAVIRIN AWARDED PRIORITY REVIEW STATUS BY JAPANESE REGULATORY AGENCY
September 15, 2005
The combination of Pegasys (peginterferon alfa-2a (40KD)) plus Copegus (ribavirin) has been awarded priority review status by the Japanese Regulatory Agency (MHLW). This brings forward the review time by approximately 6 months, with approval of the combination expected in Q3, 2006, Roche and Chugai announced here. The filing was based on results from a landmark phase III Japanese clinical trial showing that 61% of treatment naïve genotype 1b patients who received Pegasys plus Copegus achieved a sustained virological response (which is indicative of a cure) compared with 26% of patients who received Pegasys alone.
Pharmabiz (http://www.pharmabiz.com/article/detnews.asp?articleid=29371)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct